Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Mirati Therapeutics, Inc. (MRTX)
Sector: Healthcare; Industry: Biotechnology

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2023-01-18 Cherrington Julie M Director Sell 2,546 $44.66 $113,704 No
2023-01-17 Meek David D. Chief Executive Officer Sell 3,179 $42.38 $134,715 No
2023-01-17 Christensen Jamie EVP, Chief Scientific Officer Sell 2,245 $42.38 $95,142 No
2023-01-04 BAUM CHARLES M President, Founder, Head of R&D Sell 3,648 $46.60 $169,997 No
2023-01-04 Christensen Jamie EVP, Chief Scientific Officer Sell 1,949 $46.60 $90,823 No
2022-12-21 BAUM CHARLES M President, Founder, Head of R&D Sell 9,092 $40.42 $367,469 No
2022-12-21 Hickey Benjamin EVP, Chief Commercial Officer Sell 3,248 $40.41 $131,266 No
2022-12-21 Meek David D. Chief Executive Officer Sell 4,616 $40.41 $186,552 No
2022-12-16 Christensen Jamie EVP, Chief Scientific Officer Sell 2,410 $43.00 $103,624 No
2022-12-02 Christensen Jamie EVP, Chief Scientific Officer Sell 1,726 $90.19 $155,667 No
2022-11-28 BAUM CHARLES M President, Founder, Head of R&D Sell 69,256 $100.00 $6,925,600 Yes
2022-08-12 CARTER BRUCE L A Director Sell 10,000 $85.49 $854,899 Yes
2022-05-23 Christensen Jamie EVP, Chief Scientific Officer Sell 624 $63.54 $39,649 No
2022-02-11 FUCHS HENRY J Director Sell 11,000 $105.61 $1,161,717 Yes
2022-01-19 Cherrington Julie M Director Sell 1,475 $116.07 $171,203 No
2022-01-18 Christensen Jamie EVP, Chief Scientific Officer Sell 627 $120.51 $75,558 Yes
2022-01-18 BAUM CHARLES M President, Founder, Head of R&D Sell 2,517 $120.48 $303,253 Yes
2022-01-18 Hickey Benjamin EVP, Chief Commercial Officer Sell 627 $120.48 $75,543 Yes
2022-01-07 Hickey Benjamin EVP, Chief Commercial Officer Sell 1,964 $135.94 $266,984 No
2022-01-07 REED VICKIE S SVP, Chief Accounting Officer Sell 345 $135.94 $46,900 No
2022-01-04 BAUM CHARLES M President, Founder, Head of R&D Sell 4,114 $147.75 $607,855 No
2022-01-04 Christensen Jamie EVP, Chief Scientific Officer Sell 1,442 $147.72 $213,017 No
2022-01-04 REED VICKIE S SVP, Chief Accounting Officer Sell 758 $147.74 $111,987 No
2021-12-06 Christensen Jamie EVP, Chief Scientific Officer Sell 1,201 $130.79 $157,078 No
2021-12-03 BAUM CHARLES M President & Head of R&D Sell 47,204 $133.20 $6,287,687 Yes
2021-05-24 Christensen Jamie EVP, Chief Scientific Officer Sell 435 $154.34 $67,138 No
2021-04-05 CARTER BRUCE L A Director Sell 2,250 $177.11 $398,507 Yes
2021-03-19 Hickey Benjamin EVP, Chief Commercial Officer Sell 2,369 $176.44 $417,978 Yes
2021-03-10 Braslyn Ltd. 10%-Owner Sell 12,381 $197.64 $2,446,924 Yes
2021-03-05 Boxer Capital, LLC 10%-Owner Sell 400,005 $181.15 $72,460,905 Yes

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.